Friday, July 31, 2026

Coupang Cuts D.C. Lobbying 30% to $2.27M: Does Washington See Korea’s Crackdown as Discriminatory Anyway?

Coupang's lobbying expenses in D.C. dropped 30%, raising concerns of potential discrimination by the U.S. government amid scrutiny.

How to Secure Your AI Systems: Key Recommendations from Global Cybersecurity Leaders

The National Intelligence Service urges early security measures in AI development to mitigate risks and vulnerabilities in supply chains.

‘Despicable Me 4’ Director Reveals Why BTS-Blackpink Song Was Included in the Soundtrack

Chris Renaud, has personally explained why he chose to include songs from K-POP artists BTS and BLACKPINK in the film.

Tag: autoimmune diseases

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

Celltrion Files for European Approval of Cosentyx Biosimilar, Targets $6.7 Billion Market

Celltrion has filed for European approval of its CT-P55 biosimilar for autoimmune diseases, aiming for early market entry and expansion.

Cevidoplenib: The Game-Changing Autoimmune Drug Set for Global Launch in 2026

Oscotec's Cevidoplenib, an autoimmune drug, is set for global development with Agios, promising significant growth and revenue potential.

How Penetrium’s Innovative Approach Could Change Cancer Treatment Forever

Penetrium Bioscience will unveil a new therapeutic mechanism for treating cancer and other diseases on April 16 in Seoul.

Imeroprubart vs. Batoclimab: Which Treatment Will Revolutionize Graves’ Disease Management?

HanAll Biopharma's Imeroprubart targets Graves' disease, showing promise with IgG suppression and user-friendly auto-injector delivery.

Celltrion’s Remsima SC: The Leading Autoimmune Drug with 68% Market Share in Europe

Celltrion's treatments for autoimmune diseases and cancer maintain strong market positions in Europe, bolstered by stable prescriptions and new products.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.